Article

Cardiovascular Toxicology

, Volume 12, Issue 2, pp 135-142

First online:

Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis

  • Ornella GarroneAffiliated withMedical Oncology, Oncology Division, S. Croce General Hospital
  • , Nicola CrosettoAffiliated withDepartment of Biology, Massachusetts Institute of Technology
  • , Cristiana Lo NigroAffiliated withLaboratory of Cancer Genetics and Translational Oncology, Oncology Division, S. Croce General Hospital
  • , Tiziana CatzedduAffiliated withMedical Oncology, Oncology Division, S. Croce General Hospital
  • , Daniela VivenzaAffiliated withLaboratory of Cancer Genetics and Translational Oncology, Oncology Division, S. Croce General Hospital
  • , Martino MonteverdeAffiliated withLaboratory of Cancer Genetics and Translational Oncology, Oncology Division, S. Croce General Hospital
  • , Marco MerlanoAffiliated withMedical Oncology, Oncology Division, S. Croce General Hospital
  • , Mauro FeolaAffiliated withCardiovascular Rehabilitation-Heart Failure Unit, Ospedale SS Trinità Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Anthracyclines are active drugs against breast cancer, but can exert cardiotoxic effects. We analyzed the association between the kinetics of various biomarkers during chemotherapy, and the risk of subsequent cardiac toxicity. 50 patients (49 women) with early breast cancer surgically treated and eligible to anthracycline-based adjuvant chemotherapy were analyzed. The left ventricular ejection fraction (LVEF) together with the plasma concentration of several blood markers was measured at the beginning of anthracycline chemotherapy (t 0), 5 months (t 1), 16 months (t 2), 28 months (t 3), and 40 months later (t 4). A single measured LVEF value less than 50% or a clinically overt congestive heart failure (CHF) was considered cardiotoxic effects. We tested whether the kinetics of LVEF and blood biomarkers measured during chemotherapy was predictive of subsequent cardiotoxicity and overall cardiac fitness. The left ventricular ejection fraction measured at the end of treatment as well as the rate of change of hemoglobin concentration during anthracycline-based chemotherapy predicted cardiotoxicity in a 3-year follow-up period. When LVEF at the end of chemotherapy was lower than 53% or hemoglobin blood concentration declined more than 0.33 g/dL/month during chemotherapy, the odds ratio of subsequent cardiotoxicity was 37.3 and 18, respectively. The specificity of these two tests was 93.3% and 80%, whereas the sensitivity was 90.9 and 81.2%, respectively. Testing the rate of change of hemoglobin concentration during anthracycline-based chemotherapy, as well as the left ventricular ejection fraction at the end of treatment, seems a powerful method to assess the effects of anthracyclines on cardiac fitness and identify patients at high risk of CHF. Further validation of these tests on a large cohort of patients and cost-benefit analysis should be encouraged.

Keywords

Anthracycline cardiotoxicity Breast cancer Biomarkers